Mohamad Saleh, MD, PhD

Medical Director

Meet Your Tampa, FL Medical Director

dr-mojamad-saleh Mohamad Saleh, MD,PhD, is the Medical Director for our Tampa,FL clinic. He holds a medical degree from Damascus University College of Medicine, and he holds a PhD from East Tennessee State University.

After completing residencies at St.Louis University and the University of South Florida Dr. Saleh went on to start his private practice and to work at Holms Regional Medical Center and Moffitt Cancer Center. In addition, Dr. Saleh is certified with the American Board of Neurology and Psychiatry.

  • American Board of Neurology and Psychiatry

  • 1974-1980 Undergraduate
    Damascus University College of Medicine
    Degree-B.A
  • 1984-1988 UNdergraduate
    East Tennessee State University
    Degree-Doctorate
  • 2013-Present
    Moffitt Cancer Center
    General Neurology Locum Tenens Neurologist for In-Inpatient and outpatient care.
    Tampa, Florida.
  • 2012-Present
    Holms Regional Medical center
    Locum Tentant,Stoke, neuro hospital coverage.
  • 1992-Present
    Private Practice
    Stroke, Neuro-Hospitalist,
    Neuro-Imaging, Spine care.
  • Kostrzewa, RM and MI Saleh. “Attenuation of SCH 23390-induced alteration of striatal dopamine D1 receptor ontogeny by prolyl-leucyl-glycinamide in the rat.”Neuropharmacology 28(8):805-10, 1989 August.
  • Kostrzewa, RM and MI Saleh. “Impaired ontogeny of striatal dopamine D1 and D2 binding sites after postnatal treatment of rats with SCH-23390 and spiroperidol.”Developmental Brain Research 45(1):95-101, 1989 January 1.
  • Saleh, MI and RM Kostrzewa. “Impaired striatal dopamine receptor development:Differential D-1 regulation in adults.” European Journal of Pharmacology 154(3):305-11, 1988 September 23.

If you or a loved one is living with a lung disease and would like to learn more about all available treatment options, we can help. Please contact a patient coordinator today at (800) 729-3065 to schedule a free consultation.

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. The Lung Institute is firmly in accordance with the conditions set by the FDA for exemption status and conducts itself in full accordance with current guidelines. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and stem cell procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.